Theratechnologies Inc. (T:TH)
Business Focus: Biopharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 2015 Peel Street, 11th Floor MONTREAL QC H3A 1T8 |
| Tel: | 1-438-3156608 |
| Website: | https://www.theratech.com |
| IR: | See website |
| Key People | ||
| Paul Levesque President, Chief Executive Officer, Director | Philippe Dubuc Chief Financial Officer, Senior Vice President | Christian Marsolais Senior Vice President, Chief Medical Officer |
| Marienoel Colussi Vice President - Finance | Andre Dupras Vice President of Human Resources | Jocelyn Lafond General Counsel, Company Secretary | John Leasure Global Commercial Officer |
| Business Overview |
| Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. |
| Financial Overview |
| For the three months ended 29 February 2024, Theratechnologies Inc revenues decreased 18% to $16.2M. Net loss decreased 57% to $4.5M. Revenues reflect Europe segment decrease of 70% to $78K. Lower net loss reflects Research and development expenses decrease of 60% to $3.8M (expense), G/L on debt restructuring decrease from $2.7M (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.43 to -$0.09. |
| Employees: | 89 as of Nov 30, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $107.62M as of Feb 29, 2024 |
| Annual revenue (TTM): | $106.68M as of Feb 29, 2024 |
| EBITDA (TTM): | -$6.25M as of Feb 29, 2024 |
| Net annual income (TTM): | -$24.58M as of Feb 29, 2024 |
| Free cash flow (TTM): | -$7.71M as of Feb 29, 2024 |
| Net Debt Last Fiscal Year: | $28.26M as of Feb 29, 2024 |
| Shares outstanding: | 45,979,758 as of Apr 11, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
